Newer Personalised Treatment for Nasal Polyps, Asthma & Allergy Management: A Complete Guide to Precision ENT Care in Ahmedabad

🩺 AI Summary

Nasal polyps, asthma and allergy are not three separate diseases — they are connected expressions of one “united airway”, usually driven by the same type 2 inflammation. Newer personalised treatment now matches the right therapy to the right patient using biomarkers (blood eosinophils, IgE, FeNO), 4K UHD diagnostic endoscopy, allergen immunotherapy and targeted biologic medicines such as dupilumab, omalizumab, mepolizumab and tezepelumab — reducing dependence on repeated steroid courses and repeat surgeries. This guide explains causes, red-flag symptoms, modern diagnosis, medical and surgical options (including coblation and laser-assisted techniques), prevention, and when to consult an ENT specialist at Harsiddh ENT Clinic, Ghatlodiya or Shaleen Multispecialty Hospital, Sola, Ahmedabad.

Key Takeaways

• One airway, one disease. The nose, sinuses and lungs form a single connected respiratory system. Chronic rhinosinusitis with nasal polyps (CRSwNP), asthma and allergic rhinitis frequently coexist and should be treated together, not in isolation.
• Type 2 inflammation is the common engine. Immune messengers such as IL-4, IL-5 and IL-13, along with IgE antibodies and eosinophils, drive most cases of nasal polyps, allergic asthma and allergy — and they can now be measured and targeted.
• Personalisation is the new standard. Biomarker testing (blood eosinophil count, total and specific IgE, FeNO) allows ENT and chest specialists to select the treatment most likely to work for your biology.
• Biologics have changed the game. Monoclonal antibodies such as dupilumab, omalizumab, mepolizumab, benralizumab and tezepelumab can shrink polyps, restore smell, and control severe asthma — often reducing the need for repeat surgery.
• Surgery is safer and more precise than ever. 4K UHD endoscopy-guided sinus surgery, microdebrider polypectomy, coblation turbinate reduction and laser-assisted techniques offer faster recovery, and cashless ENT surgery options are available in Ahmedabad.
• Allergen immunotherapy remains the only disease-modifying allergy treatment. Three-year courses of subcutaneous or sublingual immunotherapy can retrain the immune system and may prevent allergic rhinitis progressing to asthma.
• Early specialist assessment prevents complications. Persistent blockage, loss of smell, night-time cough or wheeze lasting more than 12 weeks warrants evaluation at a dedicated ENT centre.

Introduction: Why “One Airway, One Disease” Changes Everything

If you have ever typed “my nasal polyps story” into a search engine at 2 a.m. after reading resources from the Asthma and Allergy Foundation, you are not alone — and you are exactly the person this guide was written for. Newer personalised treatment for nasal polyps, asthma and allergy management has advanced more in the last five years than in the previous fifty, and most patients simply have not been told.

Consider a typical story we see at our clinic: a 38-year-old from Ghatlodiya who has used a steroid nasal spray for years, had sinus surgery once, still cannot smell her morning chai, and now needs her asthma inhaler twice a week. For decades, each specialist treated one organ — the chest physician treated the lungs, the ENT surgeon treated the nose, the dermatologist treated the eczema. Today we understand these are branches of the same tree, rooted in shared immune mechanisms.

In this comprehensive guide, you will learn what nasal polyps, asthma and allergy really are; why they cluster together; the red-flag symptoms you should never ignore; how modern diagnosis works (including 4K UHD endoscopy and biomarker blood tests); and the complete spectrum of treatments — from intranasal sprays and allergen immunotherapy to cutting-edge biologic injections, coblation, laser-assisted procedures and endoscopic sinus surgery.

Every recommendation here is grounded in current international guidelines and peer-reviewed research cited at the end of the article, and reflects how we practise precision ENT care at Harsiddh ENT Clinic, Ghatlodiya and Shaleen Multispecialty Hospital, Sola, Ahmedabad.

Related: Functional Endoscopic Sinus Surgery (FESS) in Ahmedabad

What Are Nasal Polyps, Asthma and Allergies? Understanding the United Airway

Before we discuss newer personalised treatment, it helps to understand the three conditions individually — and then see how they interlock.

Nasal Polyps (Chronic Rhinosinusitis with Nasal Polyps – CRSwNP)

Nasal polyps are soft, painless, non-cancerous, teardrop-shaped growths that arise from the inflamed lining of the nose and sinuses. They usually appear on both sides, typically growing from the middle meatus (the drainage channel of the sinuses). A single small polyp may cause no symptoms, but clusters of polyps can block airflow, obstruct sinus drainage and progressively erase the sense of smell.

Doctors diagnose chronic rhinosinusitis with nasal polyps when symptoms such as nasal blockage, discharge, facial pressure or reduced smell persist for 12 weeks or longer, combined with polyps seen on endoscopy or sinus inflammation on a CT scan. CRSwNP affects roughly 1–4% of the general population and is far more than a “nose problem” — it carries a measurable burden on sleep, productivity and mental health.

Asthma

Asthma is the most common chronic inflammatory disease of the lungs, affecting children and adults worldwide, with prevalence rising in regions adopting urbanised, Western-style lifestyles [5]. It is characterised by variable airflow limitation — the airways intermittently narrow — and bronchial hyperresponsiveness, meaning the airways overreact to triggers like dust, cold air, smoke or viral infections. The result is the classic quartet of wheeze, breathlessness, chest tightness and cough, typically worse at night and early morning.

Asthma is not one disease but a collection of phenotypes (observable patterns, such as allergic asthma or late-onset eosinophilic asthma) driven by distinct underlying endotypes (molecular mechanisms). This phenotypic diversity, shaped by genetics and environment, is precisely why personalised medicine matters so much in asthma care [2][9].

Allergy and Allergic Rhinitis

Allergic rhinitis is an IgE-mediated inflammation of the nasal lining triggered by harmless substances — house dust mites, pollens, moulds, pet dander — that the immune system mistakenly identifies as threats. It causes sneezing, itching, watery discharge and congestion, and it significantly impairs quality of life, work performance and school productivity [3]. Allergic rhinitis is a major risk factor for developing asthma, and the two conditions worsen each other when untreated.

Allergy often extends beyond the nose. Atopic dermatitis (eczema) is a common inflammatory skin disorder with recurrent itchy lesions and a substantial psychosocial impact, and it frequently coexists with — or precedes — allergic rhinitis and asthma in the sequence doctors call the atopic march [1].

The United Airway Concept

The nose and lungs are lined by similar respiratory epithelium and share immune circuitry. This is the “united airway disease” or “one airway, one disease” model: inflammation in the nose amplifies inflammation in the bronchi and vice versa. The majority of patients with CRSwNP have lower airway involvement, and more than half of patients with severe CRSwNP also have asthma [10]. Conversely, uncontrolled rhinitis and sinus disease are recognised respiratory comorbidities that destabilise asthma [6].

Type 2 Inflammation: The Common Engine

Most nasal polyps (in Western and increasingly in Indian populations), most allergic asthma and most allergic rhinitis share type 2 (T2) inflammation. Helper T-cells (Th2) and innate lymphoid cells release the signalling proteins IL-4, IL-5 and IL-13, which drive IgE antibody production, summon eosinophils, stimulate mucus glands and remodel airway walls. Understanding this biology is the foundation of every newer personalised treatment discussed below — because IL-4, IL-5, IL-13 and IgE are exactly what today’s biologic drugs are designed to switch off [7][10].

Causes and Risk Factors of Nasal Polyps, Asthma and Allergy

Why does one person breeze through spring while another develops polyps, wheeze and eczema? The answer lies in an interplay of genes, environment and immune programming.

1. Genetics and Epigenetics

Asthma has a strong hereditary component: children of asthmatic parents carry a substantially higher risk. Genome-wide association studies have identified multiple susceptibility regions — the 17q21 locus (containing the ORMDL3 gene) being one of the best replicated. Yet genes are only part of the story. Epigenetics — chemical switches such as DNA methylation that turn genes on or off without changing the genetic code — explains how environment (pollution, tobacco smoke, early infections, diet) modifies asthma risk across a lifetime and even across generations [2]. Modern research is now layering genomics with transcriptomics, proteomics and metabolomics to map each patient’s unique disease signature [9].

2. Allergic Sensitisation and Aeroallergen Exposure

House dust mites are the dominant indoor allergen in humid climates; pollens, mould spores and animal dander dominate outdoors. In Ahmedabad, patients additionally contend with high ambient particulate pollution, construction dust and seasonal pollen surges — all established aggravators of rhinitis and asthma. Early and heavy allergen exposure in a genetically susceptible person promotes IgE sensitisation, the first step of the allergic cascade [4][5].

3. Aspirin-Exacerbated Respiratory Disease (AERD / Samter’s Triad)

A distinctive and aggressive phenotype affects adults who develop the triad of asthma + nasal polyps + sensitivity to aspirin or other NSAIDs (e.g., ibuprofen, diclofenac). These patients often have severe, rapidly recurrent polyps and difficult-to-control asthma. Recognising AERD changes management — including consideration of aspirin desensitisation and early biologic therapy.

4. Eosinophilic Inflammation and Late-Onset Disease

Adults who develop asthma after age 40 frequently have eosinophilic asthma — driven by IL-5 and marked by elevated blood eosinophils — and this group has a striking overlap with nasal polyps. Blood eosinophil counts are today used both as a diagnostic biomarker and as a predictor of response to anti-IL-5 and other biologics [7][12].

5. Respiratory Comorbidities and Systemic Factors

Asthma rarely travels alone. Rhinosinusitis, allergic rhinitis, gastro-oesophageal reflux (GERD), obesity, obstructive sleep apnoea and anxiety are all common respiratory and non-respiratory comorbidities that mimic or worsen asthma symptoms and must be actively looked for [6]. Additional risk factors include:

• Tobacco smoke (active and passive) — worsens severity and blunts steroid response
• Occupational exposures — flour dust, chemical fumes, isocyanates, textile dust
• Viral respiratory infections in early childhood — a powerful programming event for asthma
• Obesity — promotes a distinct, harder-to-treat non-T2 asthma phenotype
• Urban air pollution (PM2.5/PM10, NO₂) — impairs airway epithelial barriers
• Reduced microbial diversity in infancy (“hygiene hypothesis”) — shifts immune balance toward allergy [5]
• Family history of atopy — eczema, hay fever or asthma in first-degree relatives [1]
  | Condition | Strongest Risk Factors |
  |—|—|
  | Nasal polyps (CRSwNP) | Adult-onset asthma, AERD/NSAID sensitivity, eosinophilic inflammation, recurrent sinus infections, cystic fibrosis (in children) |
  | Asthma | Family history, allergic sensitisation, early viral infections, tobacco smoke, obesity, occupational allergens [2][5] |
  | Allergic rhinitis/atopy | Atopic family history, dust mite and pollen exposure, urban pollution, early-life eczema [1][3][4] |

Signs and Symptoms: When Mild Becomes Severe

Symptoms of these three conditions overlap, which is why self-diagnosis fails and a structured ENT evaluation matters.

Nasal Polyp Symptoms

• Persistent nasal blockage, usually on both sides, not relieved by decongestant sprays
• Reduced or lost sense of smell (hyposmia/anosmia) — often the earliest and most distressing complaint; taste is usually diminished with it
• Runny nose and post-nasal drip — mucus trickling down the throat, causing throat clearing and cough
• Facial pressure or fullness over the cheeks, forehead or between the eyes
• Snoring, mouth breathing and disturbed sleep — large polyps can aggravate obstructive sleep apnoea
• In severe disease, visible widening of the nasal bridge is rarely seen; polyps may be visible at the nostril

Asthma Symptoms

• Wheezing — a whistling sound on breathing out
• Breathlessness, especially with exertion, laughter or cold air
• Chest tightness — a band-like sensation
• Cough, classically nocturnal or early morning, sometimes the only symptom (cough-variant asthma)
• Symptoms vary over time and in intensity — this variability is a diagnostic hallmark [5]

Allergy Symptoms

• Paroxysms of sneezing (often 5–10 in a row, typically mornings)
• Itching of the nose, eyes, palate and ears; watery red eyes
• Clear watery nasal discharge; nasal itching leading to the “allergic salute” (upward nose rub) in children
• Allergic shiners — dark circles under the eyes from venous congestion
• Concurrent eczema flares (itchy, relapsing skin lesions) in atopic individuals [1]

Mild vs. Severe: A Practical Comparison

An accurate, personalised diagnosis is the launchpad for effective treatment. At Harsiddh ENT Clinic, evaluation follows a structured pathway rather than a one-size-fits-all prescription.

1. Detailed Clinical History

Your specialist will map the timeline of symptoms, triggers (dust, seasons, pets, NSAIDs), steroid and antibiotic courses, prior surgeries, inhaler use, occupational exposures, family history of atopy, and associated conditions such as eczema, reflux or snoring. Validated questionnaires such as SNOT-22 (sinonasal outcome) and ACQ/ACT (asthma control) quantify disease burden objectively.

2. Diagnostic Nasal Endoscopy — The Gold Standard

Rigid nasal endoscopy with a high-definition camera allows direct visualisation of polyps, pus, anatomical variations and the sinus drainage pathways. With 4K UHD endoscopy, even subtle oedema and early polypoid change in the middle meatus becomes visible, and the examination can be recorded and shown to you on screen — patients consistently tell us that finally seeing their problem is a turning point in understanding their treatment plan.

A CT scan of the paranasal sinuses (without contrast) is the standard pre-operative and staging investigation. MRI is reserved for suspected fungal disease, tumours or intracranial extension. Importantly, imaging is interpreted with endoscopy — scans alone overstate disease.

4. Allergy and Biomarker Testing

Skin prick testing remains the fastest, most economical way to demonstrate IgE sensitisation; serum specific IgE is used when antihistamines cannot be stopped. Meanwhile, the biomarker panel — blood eosinophils, total IgE and FeNO — defines the patient’s endotype and predicts response to individual biologics, turning drug selection from guesswork into precision medicine [12]. Research frontiers such as periostin and multi-omics signatures promise even finer matching in the near future [9][12].

5. Pulmonary Function Assessment

Because the nose and lungs are one airway, spirometry (with bronchodilator reversibility testing) is recommended whenever respiratory symptoms coexist with polyps. Peak-flow diaries and FeNO monitoring then track control over time [5][6].

Newer Personalised Treatment Options for Nasal Polyps, Asthma & Allergy

Treatment today is layered: control symptoms, modify the disease, and — where indicated — remove obstruction surgically, then personalise long-term prevention of recurrence. Here is the complete modern ladder.

Step 1: Foundational Medical Therapy

• Intranasal corticosteroid sprays (mometasone, fluticasone, budesonide) remain the first-line cornerstone for both CRSwNP and allergic rhinitis. The 2024–2025 ARIA-EAACI guideline revision — an EAACI-endorsed update of the Allergic Rhinitis and its Impact on Asthma guidelines — reinforces intranasal treatments as the most effective pharmacological class for rhinitis, informed by real-world mHealth evidence from apps such as MASK-air [3]. Correct spray technique (head slightly forward, aiming outward toward the ear, not the septum) doubles effectiveness.
• Saline nasal irrigation (isotonic or hypertonic) washes out allergens, mucus and inflammatory mediators; it is safe, inexpensive and improves symptom scores.
• Oral corticosteroids (short “rescue” courses) can dramatically shrink polyps — the so-called “medical polypectomy” — but repeated courses carry cumulative risks (bone, eye, metabolic), which is itself now an indication to escalate to biologics [10].
• Antihistamines (second-generation, non-sedating) control sneeze and itch in allergic rhinitis [3].
• Leukotriene receptor antagonists (montelukast) are particularly useful in AERD and in patients with both rhinitis and asthma.
• Asthma inhalers: inhaled corticosteroid (ICS)–based therapy is the bedrock of asthma control; modern strategy prefers ICS-formoterol as reliever over SABA-only regimens, with add-ons (LABA, LAMA, LTRA) by step [5].

Step 2: Allergen Immunotherapy — the Only Disease-Modifying Allergy Treatment

Allergen immunotherapy (AIT) gradually exposes the immune system to increasing doses of the culprit allergen, promoting regulatory T-cells that actively switch off the allergic response [4]. It is delivered as:

• Subcutaneous immunotherapy (SCIT) — “allergy shots”, typically weekly build-up then monthly maintenance
• Sublingual immunotherapy (SLIT) — daily tablets or drops under the tongue (dust mite, grass, pollen preparations)
  A standard course runs three years, and benefits persist for years after stopping. Evidence shows AIT not only controls allergic rhinitis but can prevent progression to asthma and prevent new sensitisations, especially in children [4][8]. For the selected patient with documented dust-mite-driven rhinitis and asthma, immunotherapy is arguably the most “curative” tool we possess.

Step 3: Biologic Therapy — the Heart of Newer Personalised Treatment

Biologics are monoclonal antibodies, given by injection every 2–8 weeks, that neutralise specific type 2 immune messengers. They represent the single biggest advance in severe CRSwNP and severe asthma care. The EUFOREA consensus recommends considering a biologic for CRSwNP in patients with bilateral polyps who have had (or are unfit for) sinus surgery and show evidence of type 2 inflammation, recurrent systemic-steroid need, significantly impaired quality of life, loss of smell and/or comorbid asthma [10].

Step 4: Advanced, Minimally Invasive Surgery

When medical therapy fails — or anatomy demands it — modern sinus surgery is dramatically safer and more precise than older generations of patients remember:

• Functional Endoscopic Sinus Surgery (FESS) with 4K UHD visualisation: ultra-high-definition cameras give the surgeon a magnified, panoramic view of delicate sinus anatomy, improving completeness and safety. Polyps are removed and natural drainage pathways restored while preserving healthy tissue. Related: FESS & 4K Endoscopic Sinus Surgery
• Microdebrider (powered shaver) polypectomy: precisely removes polyp tissue with suction-controlled blades, minimising bleeding and operative time.
• Coblation technology: radiofrequency-based coblation gently reduces enlarged turbinates and ablates tissue at low temperatures (40–70°C), causing less thermal injury, less pain and faster healing than traditional cautery — the same platform we use in coblation tonsillectomy. Related: Coblation ENT Surgery
• Laser-assisted techniques: diode/KTP lasers allow bloodless removal of selected lesions and precise turbinate reduction in suitable cases, often under local anaesthesia.
• Balloon sinuplasty: for limited disease, a micro-balloon dilates blocked sinus openings without tissue removal — a day-care, quick-recovery option. Related: Balloon Sinuplasty
• Image-guidance navigation in revision or complex anatomy adds a further layer of safety.
  Surgery and biologics are partners, not rivals: the emerging evidence-based strategy is to operate when obstruction is significant, then use topical steroids — and in recurrent/severe disease, a biologic — to keep polyps from returning [10].

Step 5: Home Care and Supportive Measures

• Daily saline rinses with sterile/distilled or previously boiled water
• Steam inhalation and humidification during dry, dusty weather
• Allergen-proof bedding encasings, hot-water weekly sheet washing, and HEPA air purification for dust-mite-allergic patients
• Strict avoidance of cigarette smoke (including passive) and incense/biomass smoke
• No self-medication with over-the-counter decongestant sprays beyond 5–7 days (risk of rebound congestion — rhinitis medicamentosa)

Treatment Options at a Glance: Pros and Cons

While not every case can be prevented, smart daily habits reduce flares, hospital visits and steroid need:

1. Take controller medicines every day, not just when symptomatic. The most common reason for “treatment failure” we see is the inhaler or nasal spray sitting in a drawer once the patient feels better. Inflammation persists silently.
2. Perfect your spray and inhaler technique. Ask your ENT specialist or asthma educator to watch you use your devices at every visit — studies repeatedly show most patients use them suboptimally [3].
3. Know and avoid your triggers. Keep a simple symptom diary for 4–6 weeks; patterns (dust exposure during home cleaning, seasonal pollens, pet contact, cold beverages at night, NSAID painkillers) quickly emerge. If you have AERD, avoid aspirin and NSAIDs unless desensitised under supervision.
4. Allergen-proof your bedroom. Encase mattress and pillows in dust-mite covers, wash bedding weekly at 60°C, minimise carpets and heavy curtains, and consider a HEPA purifier during high-pollution days.
5. Time outdoor activity. On high-AQI days in Ahmedabad, exercise indoors, keep windows closed during peak traffic hours, and use a well-fitting mask when travelling through dusty zones.
6. Stay vaccinated. Annual influenza and (for eligible patients) pneumococcal vaccination reduce infection-triggered exacerbations; COVID-19 boosters per current guidance. Patients on dupilumab can safely receive inactivated vaccines — discuss live vaccines individually with your specialist [11].
7. Treat the whole airway. Getting your allergic rhinitis and sinusitis under control measurably improves asthma control and reduces exacerbations [6][10].
8. Manage comorbidities. Weight optimisation, reflux management and sleep apnoea treatment each independently improve respiratory outcomes [6].
9. Have a written action plan. Every asthma patient should know exactly what to do when symptoms step up — which inhaler to adjust, when to start a rescue course, and when to seek emergency care [5].
10. Schedule regular reviews. Biomarker-guided follow-up (symptom scores, FeNO, eosinophils, lung function, endoscopy when needed) lets your doctor de-escalate when you are stable and escalate before you deteriorate [12].

When to See an ENT Specialist in Ahmedabad

Book an ENT consultation promptly if any of the following apply:

• Nasal blockage or discharge lasting more than 12 weeks despite pharmacy sprays
• Loss or major reduction of smell for more than a few weeks, or after every cold
• Recurrent sinus infections (more than 3–4 a year) or repeated antibiotic courses
• Asthma that is not controlled — night symptoms, frequent reliever use, or two or more steroid courses in a year [5]
• Polyp recurrence after previous surgery — this is precisely the scenario where biologics and personalised medicine shine [10]
• Loud snoring with witnessed pauses in breathing, morning headaches or excessive daytime sleepiness. Related: Snoring & Sleep Apnoea Treatment
• NSAID-triggered wheeze or nasal congestion (possible AERD)
  Seek urgent (same-day) evaluation for: a polyp or mass on one side only, recurrent nosebleeds, double vision or eye swelling, severe unrelenting headache, facial numbness, or a sudden severe asthma attack unresponsive to your reliever inhaler. Unilateral lesions must be examined on endoscopy — while most are benign, they occasionally hide serious pathology and should never be ignored.

At Harsiddh ENT Clinic, Ghatlodiya, and Shaleen Multispecialty Hospital, Sola, your evaluation includes 4K UHD diagnostic endoscopy, structured allergy and biomarker testing, and a personalised treatment plan spanning medical therapy, immunotherapy eligibility, biologic assessment and — where needed — endoscopic, coblation or laser-assisted day-care surgery with cashless ENT surgery assistance across major insurance and TPAs.

Frequently Asked Questions (FAQ)

Can nasal polyps go away without surgery?

Small polyps can shrink significantly with consistent intranasal corticosteroid sprays, short oral steroid courses and — in eligible patients — biologic injections such as dupilumab. However, large, long-standing polyps causing complete obstruction usually need endoscopic removal, followed by medical therapy to prevent recurrence [10].

What is the newest treatment for nasal polyps?

The newest treatments are biologic medicines — dupilumab, omalizumab and mepolizumab — approved for chronic rhinosinusitis with nasal polyps. They target type 2 inflammation (IL-4, IL-13, IL-5, IgE), shrink polyps, restore smell and reduce the need for steroids and repeat surgery in moderate-to-severe disease [10].

Are nasal polyps and asthma related?

Yes. Both share type 2 airway inflammation under the “united airway” concept. More than half of patients with severe nasal polyps also have asthma, and treating the nose improves lung control. Patients with both conditions — especially NSAID-sensitive (AERD) patients — need coordinated ENT and respiratory care [6][10].

How do doctors decide if I need a biologic injection?

Specialists follow consensus criteria: bilateral polyps despite sinus surgery or unfitness for surgery, plus evidence of type 2 inflammation (raised blood eosinophils/IgE), repeated oral steroid courses, poor quality of life, lost smell or coexisting asthma. Biomarker blood tests guide which specific biologic will work best for you [10][12].

Is FESS sinus surgery safe and painful?

Modern FESS performed with 4K UHD endoscopes and microdebriders is a highly precise, minimally invasive day-care or short-stay procedure. Most patients report mild pressure-type discomfort rather than pain, breathe better within days, and return to routine work in about a week. Serious complications are uncommon in experienced hands.

What is allergen immunotherapy, and does it really work?

Allergen immunotherapy gradually desensitises your immune system to a confirmed allergen (like dust mite) using scheduled injections (SCIT) or daily under-tongue tablets (SLIT) over three years. It is the only treatment proven to modify the allergic disease itself and can prevent allergic rhinitis from progressing to asthma, especially in children [4][8].

Can children receive these personalised treatments?

Yes, with age-appropriate selection. Allergen immunotherapy is well established in children with respiratory allergies and can alter their long-term disease course [4]. Several biologics are approved from 6–12 years of age for asthma and atopic dermatitis. A paediatric ENT and allergy evaluation confirms which options suit your child [1][11].

Will my nasal polyps come back after surgery?

Polyps can recur because surgery removes growths, not the underlying inflammation. Recurrence risk drops sharply with daily post-operative steroid sprays, saline irrigation, treating coexisting asthma and allergy, and — in recurrent or aggressive disease — adding biologic therapy. Regular endoscopic follow-up catches regrowth early [10].

Is cashless ENT surgery available in Ahmedabad for sinus procedures?

Yes. At Shaleen Multispecialty Hospital, Sola, eligible endoscopic sinus, coblation and laser-assisted ENT procedures are offered with cashless facility across major insurance providers and TPAs. Our team assists with pre-authorisation, documentation and claim processing, so you can focus on recovery rather than paperwork.

Which tests will I need before starting personalised treatment?

A typical workup includes 4K UHD nasal endoscopy, sinus CT if surgery is considered, skin prick testing or serum specific IgE, and biomarker blood tests (eosinophil count, total IgE), plus spirometry and FeNO when asthma coexists. These results define your endotype and match you to the most effective therapy [12].

Conclusion: The Future of Breathing Well Is Personal

The message of modern ENT science is empowering: if you suffer with blocked breathing, lost smell, wheeze or relentless sneezing, you are not destined to a lifetime of sprays, steroid courses and repeat operations. Nasal polyps, asthma and allergy are now understood as interconnected, biomarker-defined conditions of one airway — and newer personalised treatment finally targets the root type 2 inflammation rather than chasing symptoms.

From refined intranasal therapy guided by the latest ARIA-EAACI evidence [3], through disease-modifying allergen immunotherapy [4][8], to biomarker-selected biologics like dupilumab and tezepelumab that shrink polyps and steady severe allergic and eosinophilic asthma [7][10] — and, when anatomy requires it, 4K UHD endoscopic surgery, microdebrider, coblation and laser-assisted techniques with day-care recovery — every layer of care can now be tailored to your biology, lifestyle and goals.

Take the first step today. If you or a family member recognise the symptoms in this guide, book a comprehensive airway evaluation at Harsiddh ENT Clinic, Ghatlodiya or Shaleen Multispecialty Hospital, Sola, Ahmedabad. A single endoscopy and biomarker workup can launch a personalised plan that helps you breathe freely, smell your food and sleep peacefully — often faster than you imagine.

This article is for education and does not replace an individual consultation. Treatment decisions are always made jointly between you and your treating specialist.

References

1. Ständer S. Atopic dermatitis. Lancet. 2021. PMID: 32738956. https://doi.org/10.1016/S0140-6736(20)31286-1
2. Salam MT, et al. Genetics and Epigenetics in Asthma. Int J Mol Sci. 2021. PMID: 33673725. https://doi.org/10.3390/ijms22052412
3. Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments. Allergy. 2025. PMID: 41324154. https://doi.org/10.1111/all.70131
4. Roberts G, et al. EAACI Allergen Immunotherapy User’s Guide. Pediatr Allergy Immunol. 2020. PMID: 32436290. https://doi.org/10.1111/pai.13189
5. Holgate ST, et al. Asthma. Nat Rev Dis Primers. 2015. PMID: 27189668. https://doi.org/10.1038/nrdp.2015.25
6. Asthma and respiratory comorbidities. J Allergy Clin Immunol. 2024. PMID: 39542142. https://doi.org/10.1016/j.jaci.2024.11.006
7. Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024. PMID: 38146651. https://doi.org/10.1111/all.15986
8. Allergen Immunotherapy for the Prevention and Treatment of Asthma. Clin Exp Allergy. 2024. PMID: 39363801. https://doi.org/10.1111/cea.14575
9. Personalized therapeutic approaches for asthma. J Allergy Clin Immunol. 2025. PMID: 40203996. https://doi.org/10.1016/j.jaci.2025.03.025
10. Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019. PMID: 31090937. https://doi.org/10.1111/all.13875
11. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2024. PMID: 38848870. https://doi.org/10.1016/j.anai.2024.05.014
12. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020. PMID: 32893900. https://doi.org/10.1111/all.14582